AU2022320948A1 - Duplexbodies - Google Patents

Duplexbodies Download PDF

Info

Publication number
AU2022320948A1
AU2022320948A1 AU2022320948A AU2022320948A AU2022320948A1 AU 2022320948 A1 AU2022320948 A1 AU 2022320948A1 AU 2022320948 A AU2022320948 A AU 2022320948A AU 2022320948 A AU2022320948 A AU 2022320948A AU 2022320948 A1 AU2022320948 A1 AU 2022320948A1
Authority
AU
Australia
Prior art keywords
domain
seq
antibody
cdr
antibody construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022320948A
Other languages
English (en)
Inventor
Joachim Koch
Uwe Reusch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affimed GmbH
Original Assignee
Affimed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affimed GmbH filed Critical Affimed GmbH
Publication of AU2022320948A1 publication Critical patent/AU2022320948A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022320948A 2021-07-30 2022-08-01 Duplexbodies Pending AU2022320948A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21188905 2021-07-30
EP21188905.0 2021-07-30
PCT/EP2022/071490 WO2023007023A1 (en) 2021-07-30 2022-08-01 Duplexbodies

Publications (1)

Publication Number Publication Date
AU2022320948A1 true AU2022320948A1 (en) 2024-01-18

Family

ID=77168001

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022320948A Pending AU2022320948A1 (en) 2021-07-30 2022-08-01 Duplexbodies

Country Status (7)

Country Link
US (1) US20240376208A1 (cg-RX-API-DMAC7.html)
EP (1) EP4376958A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024529381A (cg-RX-API-DMAC7.html)
AU (1) AU2022320948A1 (cg-RX-API-DMAC7.html)
CA (1) CA3216098A1 (cg-RX-API-DMAC7.html)
IL (1) IL308154A (cg-RX-API-DMAC7.html)
WO (1) WO2023007023A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025257588A1 (en) 2024-06-10 2025-12-18 Affimed Gmbh Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance

Family Cites Families (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3180193A (en) 1963-02-25 1965-04-27 Benedict David Machines for cutting lengths of strip material
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US4675287A (en) 1984-07-26 1987-06-23 Scripps Clinic And Research Foundation Monoclonal antibody directed to human ganglioside GD2
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
WO1988002006A1 (fr) 1986-09-19 1988-03-24 Meiji Milk Products Company Limited Anticorps monoclonal specifique du ganglioside superficiel de cellules tumorales et hybridome le produisant
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0320015B1 (en) 1987-12-09 1994-07-20 Omron Tateisi Electronics Co. Inductive data communicating apparatus
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
GB9117522D0 (en) 1991-08-14 1991-10-02 Medical Res Council Ligands for dendritic cells, their uses and production
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム インターナショナル,インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
WO1994000569A1 (en) 1992-06-18 1994-01-06 Genpharm International, Inc. Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
IT1271461B (it) 1993-12-01 1997-05-28 Menarini Ricerche Sud Spa Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
HU221001B1 (hu) 1994-03-17 2002-07-29 Merck Patent Gmbh. Egyláncú anti-EGFR Fv-k és anti-EGFR ellenanyagok
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US5977316A (en) 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
EP0773288A3 (en) 1995-08-29 1997-07-09 Kirin Brewery Chimera animal and its method of manufacture
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
AU1583397A (en) 1996-01-30 1997-08-22 Brigham And Women's Hospital Antibodies for modulating cd47-mediated neutrophil transmigration
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US20020076695A1 (en) 1997-04-04 2002-06-20 Jeffrey S. Ross Methods for treating prostate cancer
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US7254167B2 (en) 1998-10-30 2007-08-07 Broadcom Corporation Constellation-multiplexed transmitter and receiver
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
GB9917012D0 (en) 1999-07-20 1999-09-22 Pharmacia & Upjohn Spa Combined preparations comprising antitumor agents
AU2002240338C1 (en) 2001-02-12 2007-05-17 Medarex, Inc. Human monoclonal antibodies to FC alpha receptor (CD89)
WO2002066058A1 (en) 2001-02-19 2002-08-29 Merck Patent Gmbh Modified anti-egfr antibodies with reduced immunogenicity
AU2002238052A1 (en) 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
US7230167B2 (en) 2001-08-31 2007-06-12 Syngenta Participations Ag Modified Cry3A toxins and nucleic acid sequences coding therefor
ES2645563T3 (es) 2001-11-30 2017-12-05 Amgen Fremont Inc. Animales transgénicos que portan genes de cadena ligera de Ig humana
WO2003050257A2 (en) 2001-12-06 2003-06-19 University Of Florida Targeting leukemia cells
KR101017732B1 (ko) 2002-03-01 2011-02-28 이뮤노메딕스, 인코오포레이티드 내재화 항-cd74 항체 및 그 이용방법
US8486859B2 (en) 2002-05-15 2013-07-16 Bioenergy, Inc. Use of ribose to enhance plant growth
US7904068B2 (en) 2003-06-06 2011-03-08 At&T Intellectual Property I, L.P. System and method for providing integrated voice and data services utilizing wired cordless access with unlicensed spectrum and wired access with licensed spectrum
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
EP1694706B1 (en) 2003-11-01 2012-04-04 Merck Patent GmbH Modified anti-cd52 antibody
JP4637749B2 (ja) 2003-11-11 2011-02-23 中外製薬株式会社 ヒト化抗cd47抗体
KR100845354B1 (ko) 2004-03-26 2008-07-09 화이자 프로덕츠 인코포레이티드 항-ctla-4 항체의 용도
EP1626059A1 (en) 2004-08-09 2006-02-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2
WO2006029219A2 (en) 2004-09-08 2006-03-16 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
US20120294863A1 (en) 2004-10-15 2012-11-22 Seattle Genetics, Inc. Anti-CD70 Antibody and Its Use for the Treatment and Prevention of Cancer and Immune Disorders
DE102004063494A1 (de) 2004-12-23 2006-07-13 Tegenero Ag Antikörper
US20080019905A9 (en) 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
EP1850872A4 (en) 2005-02-15 2008-10-15 Gtc Biotherapeutics Inc METHOD FOR USE OF ANTI-CD-137 ANTIBODY AS RADIOIMMUN THERAPY OR RADIO IMMUNE DETECTION MEANS
EP1703348B1 (en) 2005-03-14 2010-10-13 Omron Corporation Programmable controller system
RU2415871C2 (ru) 2005-03-31 2011-04-10 Байомедикс Инк. Моноклональное анти-cd20-антитело
US8067546B2 (en) 2005-04-19 2011-11-29 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
US8234145B2 (en) 2005-07-12 2012-07-31 International Business Machines Corporation Automatic computation of validation metrics for global logistics processes
BRPI0604215A (pt) 2005-08-17 2007-04-10 Biosigma Sa método para projetar oligonucleotìdeos para técnicas de biologia molecular
JP4860703B2 (ja) 2005-10-06 2012-01-25 ゼンコー・インコーポレイテッド 最適化された抗cd30抗体
JP2007122396A (ja) 2005-10-27 2007-05-17 Hitachi Ltd ディスクアレイ装置及びその障害対応検証方法
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類cd134(ox40)之人類單株抗體及其製造及使用方法
US7919297B2 (en) 2006-02-21 2011-04-05 Cornell Research Foundation, Inc. Mutants of Aspergillus niger PhyA phytase and Aspergillus fumigatus phytase
US7574748B2 (en) 2006-03-07 2009-08-18 Nike, Inc. Glove with support system
US7990860B2 (en) 2006-06-16 2011-08-02 Harris Corporation Method and system for rule-based sequencing for QoS
DK2038306T3 (en) 2006-06-30 2015-03-09 Novo Nordisk As ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF
US8430938B1 (en) 2006-07-13 2013-04-30 The United States Of America As Represented By The Secretary Of The Navy Control algorithm for autothermal reformer
KR101146588B1 (ko) 2006-08-11 2012-05-16 삼성전자주식회사 Fin 구조체 및 이를 이용한 핀 트랜지스터의 제조방법
CN100589507C (zh) 2006-10-30 2010-02-10 华为技术有限公司 一种拨号提示系统及方法
WO2009077483A1 (en) 2007-12-14 2009-06-25 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
KR20100014588A (ko) 2007-02-27 2010-02-10 제넨테크, 인크. 길항제 ox40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도
US7466008B2 (en) 2007-03-13 2008-12-16 Taiwan Semiconductor Manufacturing Company, Ltd. BiCMOS performance enhancement by mechanical uniaxial strain and methods of manufacture
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US9244059B2 (en) 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US20110077383A1 (en) 2007-07-03 2011-03-31 Medimmune, Llc Hinge domain engineering
PT2474557E (pt) 2007-07-16 2014-12-03 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
US8209741B2 (en) 2007-09-17 2012-06-26 Microsoft Corporation Human performance in human interactive proofs using partial credit
US8464584B2 (en) 2007-10-19 2013-06-18 Food Equipment Technologies Company, Inc. Beverage dispenser with level measuring apparatus and display
DE102008057648A1 (de) 2007-11-29 2009-06-04 Luk Lamellen Und Kupplungsbau Beteiligungs Kg Kraftübertragungsvorrichtung, insbesondere zur Leistungsübertragung zwischen einer Antriebsmaschine und einem Abtrieb
US8376279B2 (en) 2008-01-23 2013-02-19 Aurora Flight Sciences Corporation Inflatable folding wings for a very high altitude aircraft
MX2010007935A (es) 2008-01-24 2010-08-23 Novo Nordisk As Anticuerpo monoclonal humanizado anti-nkg2a humano.
DK2657253T3 (en) 2008-01-31 2017-10-09 Genentech Inc Anti-CD79b antibodies and immune conjugates and methods of use
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 항암제
EP2404668B1 (en) 2009-03-04 2014-05-07 Nissan Motor Co., Ltd. Exhaust gas purification catalyst and process for producing same
PE20120877A1 (es) 2009-04-01 2012-08-06 Genentech Inc ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
US8463191B2 (en) 2009-04-02 2013-06-11 Qualcomm Incorporated Beamforming options with partial channel knowledge
US8647623B2 (en) 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
WO2011086179A1 (en) 2010-01-15 2011-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and treatment of cutaneous t cell lymphomas
EP2542258A4 (en) 2010-03-04 2013-08-21 Vet Therapeutics Inc ON CD52 MONOCLONAL ANTIBODIES
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CN102892786B (zh) 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
EP2575881B1 (en) 2010-05-28 2016-09-14 INSERM - Institut National de la Santé et de la Recherche Médicale Anti-cd160 specific antibodies for the treatment of eye disorders based on neoangiogenesis
CN103079644B (zh) 2010-06-11 2017-02-15 协和发酵麒麟株式会社 抗tim‑3抗体
LT2609118T (lt) 2010-08-23 2017-04-25 Board Of Regents, The University Of Texas System Anti-ox40 antikūnai ir jų panaudojimo būdai
EP2658739B1 (de) 2010-12-30 2017-02-22 Johnson Controls Metals and Mechanisms GmbH & Co. KG Längsverstellvorrichtung eines kraftfahrzeugsitzes mit zwei schienenpaaren
SG191977A1 (en) 2011-02-01 2013-08-30 Genmab As Human antibodies and antibody-drug conjugates against cd74
AU2012240448A1 (en) 2011-04-01 2013-03-28 Immunogen, Inc. Compositions and methods for treatment of ovarian, peritoneal, and fallopian tube cancer
KR102119840B1 (ko) 2011-07-11 2020-06-09 아이크노스 사이언스 에스. 아. Ox40에 결합하는 항체 및 이들의 용도
JP6038920B2 (ja) 2011-08-23 2016-12-07 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 抗ox40抗体およびそれを使用する方法
JP2013193995A (ja) 2012-03-21 2013-09-30 Tokyo Medical & Dental Univ 特発性炎症性筋疾患の予防又は治療剤
JP2015516984A (ja) 2012-04-26 2015-06-18 バイオアトラ、エルエルシー 抗cd22抗体
CN111499755A (zh) 2012-08-03 2020-08-07 丹娜法伯癌症研究院 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
EP2914628A1 (en) 2012-11-01 2015-09-09 Max-Delbrück-Centrum für Molekulare Medizin An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
WO2014164067A1 (en) 2013-03-12 2014-10-09 Imaginab, Inc. Antigen binding constructs to cd30
WO2014158821A1 (en) 2013-03-12 2014-10-02 Imaginab, Inc. Antigen binding constructs to cd70
AU2014276440A1 (en) 2013-06-03 2015-11-05 Novartis Ag Combinations of an anti-PD-L1 antibody and a MEK inhibitor and/or a BRaf inhibitor
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
TR201910814T4 (tr) 2014-03-19 2019-08-21 Cellectis Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri.
CA2942150A1 (en) 2014-04-07 2015-10-15 Seattle Genetics, Inc. Stable formulations for anti-cd19 antibodies and antibody-drug conjugates
EP2930188A1 (en) 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
BR112016024546A2 (pt) 2014-04-30 2018-01-23 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft anticorpo ou fragmento de anticorpo, anticorpo ou fragmento de anticorpo isolado, conjugado de anticorpo-fármaco, molécula de ácido nucleico, célula hospedeira, e, composição farmacêutica
RU2017105425A (ru) 2014-08-28 2018-09-28 Академиш Зикенхёйс Лейден Х.О.Д.Н. Люмк Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины
US10429394B2 (en) 2014-08-29 2019-10-01 National University Corporation Hokkaido Monoclonal antibodies against KIR2DS1
US10105142B2 (en) 2014-09-18 2018-10-23 Ethicon Llc Surgical stapler with plurality of cutting elements
CN105837689B (zh) 2015-01-13 2020-06-19 博生吉安科细胞技术有限公司 抗cd19单克隆抗体及其制备方法
AR103488A1 (es) 2015-01-23 2017-05-10 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
US10100118B2 (en) 2015-04-08 2018-10-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD123
EP3307779A2 (en) 2015-06-12 2018-04-18 Alector LLC Anti-cd33 antibodies and methods of use thereof
WO2016209021A1 (ko) 2015-06-24 2016-12-29 주식회사 차바이오텍 자연살해세포의 증식 방법 및 자연살해세포 증식용 조성물
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
WO2017023780A1 (en) 2015-07-31 2017-02-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates for targeting cd56-positive tumors
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
EP3156417A1 (en) 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
US20190031785A1 (en) * 2016-01-13 2019-01-31 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
ES2904593T3 (es) 2016-01-21 2022-04-05 Pfizer Anticuerpos monoespecíficos y biespecíficos para la variante III del receptor del factor de crecimiento epidérmico y CD3 y sus usos
AU2017212739B2 (en) 2016-01-27 2024-03-21 Sutro Biopharma, Inc. Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates
CN105753986B (zh) 2016-04-24 2019-12-10 赵磊 一类抗cd20靶向抗体及用途
SMT202100317T1 (it) 2016-06-27 2021-07-12 Morphosys Ag Formulazioni di anticorpi anti-cd19
US20180208653A1 (en) 2017-01-20 2018-07-26 Beth Israel Deaconess Medical Center Methods for enhancing an immune response
US20200095327A1 (en) 2017-02-08 2020-03-26 Dragonfly Therapeutics, Inc. Antibody heavy chain variable domains targeting the nkg2d receptor
CN111050788A (zh) 2017-02-28 2020-04-21 西雅图基因公司 抗tigit抗体
US11274160B2 (en) 2017-03-02 2022-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to Nectin-4 and uses thereof
KR20190140943A (ko) 2017-04-24 2019-12-20 메모리얼 슬로안 케터링 캔서 센터 항-cd33 항체 제제
WO2019006280A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
CN111051347B (zh) 2017-09-29 2021-12-21 江苏恒瑞医药股份有限公司 Tigit抗体、其抗原结合片段及医药用途
EP3712170A4 (en) 2017-11-10 2022-03-02 Jiangsu Hengrui Medicine Co., Ltd. CD96 ANTIBODY, ANTIGEN BINDING FRAGMENT AND PHARMACEUTICAL USE THEREOF
CA3090244A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
US11673961B2 (en) 2018-02-20 2023-06-13 Memorial Sloan Kettering Cancer Center Anti-CD20 antibody and uses thereof
EP3774914A2 (en) * 2018-04-13 2021-02-17 Affimed GmbH Nk cell engaging antibody fusion constructs
JP7459043B2 (ja) 2018-07-12 2024-04-01 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ 親和性成熟cd22特異的モノクローナル抗体およびその使用
PL3843757T3 (pl) 2018-08-27 2024-08-05 Affimed Gmbh Kriokonserwowane komórki nk wstępnie obciążone konstruktem przeciwciała
EP3870608A1 (en) 2018-10-25 2021-09-01 Polpharma Biologics Utrecht B.V. Anti-human cd89 antibodies and uses thereof
US12534532B2 (en) 2018-10-26 2026-01-27 Crage Medical Co., Limited CLL1-targeting antibody and application thereof
CN111116745B (zh) 2018-11-01 2022-10-14 上海新理念生物医药科技有限公司 抗CD79b抗体、其药物偶联物及其应用
EP3878869A4 (en) 2018-11-07 2023-04-19 Shanghai Hyamab Biotech Co., Ltd. NKG2A ANTIBODIES, METHOD OF PRODUCTION THEREOF AND USE THEREOF
MX2021005708A (es) 2018-11-16 2021-09-21 Bristol Myers Squibb Co Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
JP7728701B2 (ja) * 2018-12-17 2025-08-25 レビトープ リミテッド 双子型免疫細胞エンゲージャー
WO2020135426A1 (zh) 2018-12-24 2020-07-02 信达生物制药(苏州)有限公司 全人源的抗cd30单链抗体及其应用
US20230002450A1 (en) * 2019-02-18 2023-01-05 Courier Therapeutics, Inc. Bispecific Fusion Protein Using Orthopoxvirus Major Histocompatibility Complex (MHC) Class I-Like Protein (OMCP) and Tumor-Specific Binding Partner
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス,インコーポレーテッド NKp30に結合する抗体分子およびその使用

Also Published As

Publication number Publication date
CA3216098A1 (en) 2023-02-02
WO2023007023A1 (en) 2023-02-02
IL308154A (en) 2023-12-01
US20240376208A1 (en) 2024-11-14
EP4376958A1 (en) 2024-06-05
JP2024529381A (ja) 2024-08-06

Similar Documents

Publication Publication Date Title
EP3843757B1 (en) Cryopreserved nk cells preloaded with an antibody construct
JP7717767B2 (ja) 細胞傷害性tリンパ球関連タンパク質4(ctla-4)に対する新規モノクローナル抗体
US20230365709A1 (en) Trispecific binders
CN120058939A (zh) 抗cd38抗体及与抗cd3和抗cd28抗体的组合
CA3086935A1 (en) Anti-tigit antibodies and their use as therapeutics and diagnostics
JP2017536128A (ja) ドメイン交換抗体
KR20160006168A (ko) 인간화 항-cd134(ox40) 항체 및 이의 용도
CN119278217A (zh) 新型抗gprc5d抗体、结合gprc5d和cd3的双特异性抗原结合分子以及其用途
CN119213023A (zh) Ilt3和cd3结合剂以及其使用方法
US20240376208A1 (en) Duplexbodies
TW202535947A (zh) CD33抗體、CD33/Vδ2多特異性抗體及其用途
JP7686626B2 (ja) 増強されたプロテインl捕捉動的結合容量を有する二重特異性抗原結合ポリペプチドの精製方法
RU2819927C2 (ru) Криоконсервированные клетки-естественные киллеры, предварительно нагруженные конструкцией антитела
WO2025243243A1 (en) Bispecific antibody targeting emr2 (cd312) and the t-cell receptor trbv19